These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

63 related articles for article (PubMed ID: 9752279)

  • 1. [When p19ARF finds a partner or new "dangerous liaisons"].
    Larsen CJ
    Bull Cancer; 1998 Jun; 85(6):523-6. PubMed ID: 9752279
    [TBL] [Abstract][Full Text] [Related]  

  • 2. p19ARF prevents G1 cyclin-dependent kinase activation by interacting with MDM2 and activating p53 in mouse fibroblasts.
    Kurokawa K; Tanaka T; Kato J
    Oncogene; 1999 Apr; 18(17):2718-27. PubMed ID: 10348346
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The Ink4a tumor suppressor gene product, p19Arf, interacts with MDM2 and neutralizes MDM2's inhibition of p53.
    Pomerantz J; Schreiber-Agus N; Liégeois NJ; Silverman A; Alland L; Chin L; Potes J; Chen K; Orlow I; Lee HW; Cordon-Cardo C; DePinho RA
    Cell; 1998 Mar; 92(6):713-23. PubMed ID: 9529248
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Deregulation of the p14ARF/MDM2/p53 pathway is a prerequisite for human astrocytic gliomas with G1-S transition control gene abnormalities.
    Ichimura K; Bolin MB; Goike HM; Schmidt EE; Moshref A; Collins VP
    Cancer Res; 2000 Jan; 60(2):417-24. PubMed ID: 10667596
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Cooperativity of p19ARF, Mdm2, and p53 in murine tumorigenesis.
    Moore L; Venkatachalam S; Vogel H; Watt JC; Wu CL; Steinman H; Jones SN; Donehower LA
    Oncogene; 2003 Oct; 22(49):7831-7. PubMed ID: 14586409
    [TBL] [Abstract][Full Text] [Related]  

  • 6. p16INK4A and p19ARF act in overlapping pathways in cellular immortalization.
    Carnero A; Hudson JD; Price CM; Beach DH
    Nat Cell Biol; 2000 Mar; 2(3):148-55. PubMed ID: 10707085
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Opposing effects of Ras on p53: transcriptional activation of mdm2 and induction of p19ARF.
    Ries S; Biederer C; Woods D; Shifman O; Shirasawa S; Sasazuki T; McMahon M; Oren M; McCormick F
    Cell; 2000 Oct; 103(2):321-30. PubMed ID: 11057904
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Two arginine rich domains in the p14ARF tumour suppressor mediate nucleolar localization.
    Rizos H; Darmanian AP; Mann GJ; Kefford RF
    Oncogene; 2000 Jun; 19(26):2978-85. PubMed ID: 10871849
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The human p19ARF protein encoded by the beta transcript of the p16INK4a gene is frequently lost in small cell lung cancer.
    Gazzeri S; Della Valle V; Chaussade L; Brambilla C; Larsen CJ; Brambilla E
    Cancer Res; 1998 Sep; 58(17):3926-31. PubMed ID: 9731504
    [TBL] [Abstract][Full Text] [Related]  

  • 10. N-terminal polyubiquitination and degradation of the Arf tumor suppressor.
    Kuo ML; den Besten W; Bertwistle D; Roussel MF; Sherr CJ
    Genes Dev; 2004 Aug; 18(15):1862-74. PubMed ID: 15289458
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Alternative protein p19ARF: a genuine tumor suppressor gene].
    Larsen CJ
    Bull Cancer; 1998 Apr; 85(4):304-6. PubMed ID: 9752293
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Loss of p19ARF enhances the defects of Mdm2 overexpression in the mammary gland.
    Foster CJ; Lozano G
    Oncogene; 2002 May; 21(22):3525-31. PubMed ID: 12032854
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Nucleolar Arf sequesters Mdm2 and activates p53.
    Weber JD; Taylor LJ; Roussel MF; Sherr CJ; Bar-Sagi D
    Nat Cell Biol; 1999 May; 1(1):20-6. PubMed ID: 10559859
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Expression of p16INK4a/p16alpha and p19ARF/p16beta is frequently altered in non-small cell lung cancer and correlates with p53 overexpression.
    Vonlanthen S; Heighway J; Tschan MP; Borner MM; Altermatt HJ; Kappeler A; Tobler A; Fey MF; Thatcher N; Yarbrough WG; Betticher DC
    Oncogene; 1998 Nov; 17(21):2779-85. PubMed ID: 9840942
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Mdm2: the ups and downs.
    Juven-Gershon T; Oren M
    Mol Med; 1999 Feb; 5(2):71-83. PubMed ID: 10203572
    [No Abstract]   [Full Text] [Related]  

  • 16. Mdm2: keeping p53 under control.
    Piette J; Neel H; Maréchal V
    Oncogene; 1997 Aug; 15(9):1001-10. PubMed ID: 9285554
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Activation and activities of the p53 tumour suppressor protein.
    Bálint E E; Vousden KH
    Br J Cancer; 2001 Dec; 85(12):1813-23. PubMed ID: 11747320
    [TBL] [Abstract][Full Text] [Related]  

  • 18. p19ARF links the tumour suppressor p53 to Ras.
    Palmero I; Pantoja C; Serrano M
    Nature; 1998 Sep; 395(6698):125-6. PubMed ID: 9744268
    [No Abstract]   [Full Text] [Related]  

  • 19. Loss of the ARF tumor suppressor reverses premature replicative arrest but not radiation hypersensitivity arising from disabled atm function.
    Kamijo T; van de Kamp E; Chong MJ; Zindy F; Diehl JA; Sherr CJ; McKinnon PJ
    Cancer Res; 1999 May; 59(10):2464-9. PubMed ID: 10344759
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Simulation-based validation of the p53 transcriptional activity with hybrid functional petri net.
    Doi A; Nagasaki M; Matsuno H; Miyano S
    In Silico Biol; 2006; 6(1-2):1-13. PubMed ID: 16789909
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 4.